Loading…
Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy...
Saved in:
| Published in: | Human vaccines & immunotherapeutics 2024-12, Vol.20 (1), p.2385654 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c427t-6e1d8474b35c11e054dbe22901a2447b9e668b8ca59c840b8b21aad85768fd443 |
| container_end_page | |
| container_issue | 1 |
| container_start_page | 2385654 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 20 |
| creator | Fu, Quanlan Luo, Yuandong Li, Junjie Zhang, Pingping Tang, Shuxian Song, Xinyi Fu, Jiawei Liu, Mengqi Mo, Rongmi Wei, Ming Li, Hejie Liu, Xiaosong Wang, Tianfang Ni, Guoying |
| description | Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges. |
| doi_str_mv | 10.1080/21645515.2024.2385654 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_39193797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2cf9809c19ac4dd58beb724a6d8729b5</doaj_id><sourcerecordid>3097853828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-6e1d8474b35c11e054dbe22901a2447b9e668b8ca59c840b8b21aad85768fd443</originalsourceid><addsrcrecordid>eNp9kU9v3CAQxa2qVROl-QipOPbiDWAwcGsVtelKkXpppSoXxJ8hIbKNC95W_vZhu5s9hsugmTfvIX5Nc0XwhmCJrynpGeeEbyimbEM7yXvO3jTn-37LOfv99nQn_Ky5LOUJ1yOquu_fN2edIqoTSpw399txzulvnB7Q8ggIQojOuBWlgJyZHGQUx3E3pTrMZl6RXdFjKkvrIUAdVxHkOCGyIchMvlaFZpiX6KF8aN4FMxS4PNaL5te3rz9vvrd3P263N1_uWseoWNoeiJdMMNtxRwhgzrwFShUmhjImrIK-l1Y6w5WTDFtpKTHGSy56GTxj3UWzPfj6ZJ70nONo8qqTifp_I-UHbfIS3QCauqAkVo4o45j3XFqwgjLTeymosrx6fTp41U_5s4Oy6DEWB8NgJki7ojushOSdpLJK-UHqciolQzhFE6z3lPQLJb2npI-U6t7HY8TOjuBPWy9MquDzQRCnkPJo_qU8eL2YdUg55Aol1ne8nvEM67GfLQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097853828</pqid></control><display><type>article</type><title>Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides</title><source>Taylor & Francis Open Access Journals</source><creator>Fu, Quanlan ; Luo, Yuandong ; Li, Junjie ; Zhang, Pingping ; Tang, Shuxian ; Song, Xinyi ; Fu, Jiawei ; Liu, Mengqi ; Mo, Rongmi ; Wei, Ming ; Li, Hejie ; Liu, Xiaosong ; Wang, Tianfang ; Ni, Guoying</creator><creatorcontrib>Fu, Quanlan ; Luo, Yuandong ; Li, Junjie ; Zhang, Pingping ; Tang, Shuxian ; Song, Xinyi ; Fu, Jiawei ; Liu, Mengqi ; Mo, Rongmi ; Wei, Ming ; Li, Hejie ; Liu, Xiaosong ; Wang, Tianfang ; Ni, Guoying</creatorcontrib><description>Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges.</description><identifier>ISSN: 2164-5515</identifier><identifier>ISSN: 2164-554X</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2024.2385654</identifier><identifier>PMID: 39193797</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Animals ; Antimicrobial Cationic Peptides - immunology ; Antimicrobial Cationic Peptides - therapeutic use ; Caerin 1 peptide ; Humans ; immune checkpoint blockade ; Immunotherapy - methods ; macrophage ; Neoplasms - immunology ; Neoplasms - therapy ; Peptides - immunology ; Peptides - therapeutic use ; therapeutic vaccine ; tumor microenvironment ; Tumor Microenvironment - immunology</subject><ispartof>Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2385654</ispartof><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c427t-6e1d8474b35c11e054dbe22901a2447b9e668b8ca59c840b8b21aad85768fd443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2385654$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/21645515.2024.2385654$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27478,27900,27901,59115,59116</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39193797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fu, Quanlan</creatorcontrib><creatorcontrib>Luo, Yuandong</creatorcontrib><creatorcontrib>Li, Junjie</creatorcontrib><creatorcontrib>Zhang, Pingping</creatorcontrib><creatorcontrib>Tang, Shuxian</creatorcontrib><creatorcontrib>Song, Xinyi</creatorcontrib><creatorcontrib>Fu, Jiawei</creatorcontrib><creatorcontrib>Liu, Mengqi</creatorcontrib><creatorcontrib>Mo, Rongmi</creatorcontrib><creatorcontrib>Wei, Ming</creatorcontrib><creatorcontrib>Li, Hejie</creatorcontrib><creatorcontrib>Liu, Xiaosong</creatorcontrib><creatorcontrib>Wang, Tianfang</creatorcontrib><creatorcontrib>Ni, Guoying</creatorcontrib><title>Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges.</description><subject>Animals</subject><subject>Antimicrobial Cationic Peptides - immunology</subject><subject>Antimicrobial Cationic Peptides - therapeutic use</subject><subject>Caerin 1 peptide</subject><subject>Humans</subject><subject>immune checkpoint blockade</subject><subject>Immunotherapy - methods</subject><subject>macrophage</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Peptides - immunology</subject><subject>Peptides - therapeutic use</subject><subject>therapeutic vaccine</subject><subject>tumor microenvironment</subject><subject>Tumor Microenvironment - immunology</subject><issn>2164-5515</issn><issn>2164-554X</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>DOA</sourceid><recordid>eNp9kU9v3CAQxa2qVROl-QipOPbiDWAwcGsVtelKkXpppSoXxJ8hIbKNC95W_vZhu5s9hsugmTfvIX5Nc0XwhmCJrynpGeeEbyimbEM7yXvO3jTn-37LOfv99nQn_Ky5LOUJ1yOquu_fN2edIqoTSpw399txzulvnB7Q8ggIQojOuBWlgJyZHGQUx3E3pTrMZl6RXdFjKkvrIUAdVxHkOCGyIchMvlaFZpiX6KF8aN4FMxS4PNaL5te3rz9vvrd3P263N1_uWseoWNoeiJdMMNtxRwhgzrwFShUmhjImrIK-l1Y6w5WTDFtpKTHGSy56GTxj3UWzPfj6ZJ70nONo8qqTifp_I-UHbfIS3QCauqAkVo4o45j3XFqwgjLTeymosrx6fTp41U_5s4Oy6DEWB8NgJki7ojushOSdpLJK-UHqciolQzhFE6z3lPQLJb2npI-U6t7HY8TOjuBPWy9MquDzQRCnkPJo_qU8eL2YdUg55Aol1ne8nvEM67GfLQ</recordid><startdate>20241231</startdate><enddate>20241231</enddate><creator>Fu, Quanlan</creator><creator>Luo, Yuandong</creator><creator>Li, Junjie</creator><creator>Zhang, Pingping</creator><creator>Tang, Shuxian</creator><creator>Song, Xinyi</creator><creator>Fu, Jiawei</creator><creator>Liu, Mengqi</creator><creator>Mo, Rongmi</creator><creator>Wei, Ming</creator><creator>Li, Hejie</creator><creator>Liu, Xiaosong</creator><creator>Wang, Tianfang</creator><creator>Ni, Guoying</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20241231</creationdate><title>Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides</title><author>Fu, Quanlan ; Luo, Yuandong ; Li, Junjie ; Zhang, Pingping ; Tang, Shuxian ; Song, Xinyi ; Fu, Jiawei ; Liu, Mengqi ; Mo, Rongmi ; Wei, Ming ; Li, Hejie ; Liu, Xiaosong ; Wang, Tianfang ; Ni, Guoying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-6e1d8474b35c11e054dbe22901a2447b9e668b8ca59c840b8b21aad85768fd443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antimicrobial Cationic Peptides - immunology</topic><topic>Antimicrobial Cationic Peptides - therapeutic use</topic><topic>Caerin 1 peptide</topic><topic>Humans</topic><topic>immune checkpoint blockade</topic><topic>Immunotherapy - methods</topic><topic>macrophage</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Peptides - immunology</topic><topic>Peptides - therapeutic use</topic><topic>therapeutic vaccine</topic><topic>tumor microenvironment</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fu, Quanlan</creatorcontrib><creatorcontrib>Luo, Yuandong</creatorcontrib><creatorcontrib>Li, Junjie</creatorcontrib><creatorcontrib>Zhang, Pingping</creatorcontrib><creatorcontrib>Tang, Shuxian</creatorcontrib><creatorcontrib>Song, Xinyi</creatorcontrib><creatorcontrib>Fu, Jiawei</creatorcontrib><creatorcontrib>Liu, Mengqi</creatorcontrib><creatorcontrib>Mo, Rongmi</creatorcontrib><creatorcontrib>Wei, Ming</creatorcontrib><creatorcontrib>Li, Hejie</creatorcontrib><creatorcontrib>Liu, Xiaosong</creatorcontrib><creatorcontrib>Wang, Tianfang</creatorcontrib><creatorcontrib>Ni, Guoying</creatorcontrib><collection>Taylor & Francis Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fu, Quanlan</au><au>Luo, Yuandong</au><au>Li, Junjie</au><au>Zhang, Pingping</au><au>Tang, Shuxian</au><au>Song, Xinyi</au><au>Fu, Jiawei</au><au>Liu, Mengqi</au><au>Mo, Rongmi</au><au>Wei, Ming</au><au>Li, Hejie</au><au>Liu, Xiaosong</au><au>Wang, Tianfang</au><au>Ni, Guoying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2024-12-31</date><risdate>2024</risdate><volume>20</volume><issue>1</issue><spage>2385654</spage><pages>2385654-</pages><issn>2164-5515</issn><issn>2164-554X</issn><eissn>2164-554X</eissn><abstract>Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>39193797</pmid><doi>10.1080/21645515.2024.2385654</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2385654 |
| issn | 2164-5515 2164-554X 2164-554X |
| language | eng |
| recordid | cdi_pubmed_primary_39193797 |
| source | Taylor & Francis Open Access Journals |
| subjects | Animals Antimicrobial Cationic Peptides - immunology Antimicrobial Cationic Peptides - therapeutic use Caerin 1 peptide Humans immune checkpoint blockade Immunotherapy - methods macrophage Neoplasms - immunology Neoplasms - therapy Peptides - immunology Peptides - therapeutic use therapeutic vaccine tumor microenvironment Tumor Microenvironment - immunology |
| title | Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-25T06%3A08%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improving%20the%20efficacy%20of%20cancer%20immunotherapy%20by%20host-defence%20caerin%201.1%20and%201.9%20peptides&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Fu,%20Quanlan&rft.date=2024-12-31&rft.volume=20&rft.issue=1&rft.spage=2385654&rft.pages=2385654-&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2024.2385654&rft_dat=%3Cproquest_pubme%3E3097853828%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c427t-6e1d8474b35c11e054dbe22901a2447b9e668b8ca59c840b8b21aad85768fd443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3097853828&rft_id=info:pmid/39193797&rfr_iscdi=true |